Table 3 Correlations between 24-h MTX level and clinical factors.
Variables | Univariate logistic regression–odds ratio (95% CI) | P-value | Multivariate logistic regression with generalized estimating equation–adjusted odds ratio (95% CI) | P-value | |
|---|---|---|---|---|---|
Age | 1.09 (1.04–1.14) | < 0.001*** | − 0.070 (− 0.119– − 0.020) | 0.006** | |
Gender | 1.73 (0.59–5.12) | 0.320 | |||
Body surface area (kg/m2) | 0.76 (0.15–13.64) | 0.760 | |||
Chemotherapy regimens | High-dose MTX | 2.73 (0.1–7.48) | 0.050 | ||
High-dose MTX and Rituximab | 3.57 (1.16–11.04) | 0.030* | |||
High-dose MTX-Ifosfamide | 0.68 (0.18–2.53) | 0.570 | |||
High-dose MTX-Ifosfamide and Rituximab | 0.72 (0.15–3.42) | 0.680 | |||
Aspa/Met/Dex + BV$ | 0.00 | 0.999 | |||
Aspa/Met/Dex | 0.26 (0.03–2.04) | 0.199 | |||
Acute lymphoblastic leukemia induction protocol | 0.00 | 0.999 | |||
Hyper-CVAD& | 0.00 | 1.000 | |||
CODOX-M/IVAC# | 0.00 | 0.999 | |||
Co-morbidities | Diabetes mellitus | 3.01 (1.05–8.63) | 0.040* | ||
Hypertension | 10.38 (3.62–29.77) | < 0.001*** | 1.716 (0.556–2.875)** | 0.004** | |
Dyslipidemia | 3.23 (1.12–9.33) | 0.030* | |||
Chronic kidney disease | 0.00 | 0.999 | |||
Solid cancer | 0.00 | 0.999 | |||
Atrial fibrillation/Myocardial infarction | 6.75 (1.53–29.71) | 0.012* | |||
HIV | 0.00 | 0.999 | |||
Viral hepatitis | 1.62 (0.48–5.49) | 0.441 | |||
Hematologic malignancy | Primary CNS lymphoma | 2.32 (0.88–6.13) | 0.090 | ||
Diffuse large B-cell lymphoma with CNS involvement | 2.02 (0.50–8.22) | 0.326 | |||
Diffuse large B-cell lymphoma with CNS prophylaxis | 1.22 (0.37–4.07) | 0.742 | |||
Burkitt lymphoma | 0.00 | 0.999 | |||
Extranodal NK/T-cell lymphoma | 0.20 (0.03–1.60) | 0.130 | |||
Acute lymphoblastic leukemia | 0.00 | 0.999 | |||
Lymphoblastic leukemia | 0.00 | 1.000 | |||
Side effect of MTX | Transaminitis | 1.16 (0.38–3.50) | 0.792 | ||
Mucositis | 0.00 | 1.000 | |||
MTX overdose in previous cycle | 13.75 (2.33–81.25) | 0.004** | |||
